第 52 卷第 4 期 Vol. 52 No. 4 2022 年 8 月 Aug 2022

所属栏目：专论与综述 EGFR抑制剂的研究进展

谢月红，周季颖，汪锦娟* （南京医科大学附属南京医院（南京市第一医院）药学部，江苏 南京 210000）

摘　要：肺癌是世界上癌症死亡的主要原因，其中非小细胞肺癌占肺癌的80%以上。在非小细胞肺癌的治疗中表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKIs）占有非常重要的地位。针对耐药性问题，目前小分子EGFR-TKIs共开发了四代。综述了EGFR抑制剂的研究进展。

关键词：小细胞肺癌；EGFR-TKIs；耐药性

中图分类号：R734.2　　文献标识码：A　　文章编号：1009-9212（2022）04-0006-08

Research Progress of EGFR Inhibitors

XIE Yue-hong, ZHOU Ji-ying, WANG Jin-juan* (Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, China)

Abstract：Lung cancer has affected human health seriously. Lung cancer provides the highest incidence rate and mortality rate in China while non-small cell lung cancer (NSCLC) accounts for 80% of lung cancer mortality. Epidermal growth factor receptor (EGFR) tyrosine kinase activity leads to recruitment and phosphorylation of several downstream intracellular substrates, leading to mitogenic signaling and tumor-promoting cellular activities. Therefore, inhibition of EGFR signaling pathway could significantly inhibit the growth and proliferation of tumor cells. The structures and functions of EGFR as well as current status of EGFR tyrosine kinase inhibitors were reviewed.

Key words：NSCLC; EGFR tyrosine kinase inhibitors; drug resistance

作者简介：谢月红（1987—），女，江苏南京人，药师，研究方向：药学（E-mail: suifengzhuliuxz@163.com）。

联 系 人：汪锦娟，主管药师，研究方向：药学。

收稿日期：2022-07-18